All In Biotech

Drug Trial Radar · NCT00738101

Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants

Last checked: Nov 20, 2026Latest source record: May 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

293

Actual

Start

Sep 2008

Primary completion

Mar 27, 2019

Study completion Mar 27, 2020

Sponsor

Lead sponsor
Baylor College of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Children's Hospital
First posted
Aug 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 14 days, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.

Conditions

  • Cholestasis
  • Cholestasis of Parenteral Nutrition

Interventions

  • OmegavenDrug

    Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of StudyTime frame: From initiation to end of study (End of Study : Discontinuation of Fish Oil Emulsion, Death, Transplant, or Discharge from the hospital, whichever is achieved first, up to 5 years).
  2. All Cause Mortality During the Study.Time frame: From initiation to end of study (End of Study : Discontinuation of Fish Oil Emulsion, Death, Transplant, or Discharge from the hospital, whichever is achieved first, up to 5 years).
  3. Growth Z-scores for WeightTime frame: From initiation to end of study (End of Study : Discontinuation of Fish Oil Emulsion, Death, Transplant, or Discharge from the hospital, whichever is achieved first, up to 5 years).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Baylor College of Medicine

    Houston, Texas

  • Texas Children's Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.